Stroke, Vol 19, 1211-1215, Copyright © 1988 by American Heart Association
G Boysen, PS Sorensen, M Juhler, AR Andersen, J Boas, JS Olsen and P Joensen
The effect of very-low-dose aspirin as an antithrombotic agent was
evaluated blindly in 301 patients who had recently undergone carotid
endarterectomy. After randomization, 150 patients received aspirin and 151
received placebo. The two groups were comparable with regard to age, sex,
blood pressure, previous cerebrovascular events, and smoking habits. The
effect of the study medication on platelet aggregation was measured twice
in each patient during the first 2 months and at each follow-up visit; the
dose was individually adjusted. In 76% of the patients receiving aspirin,
50 mg/day gave satisfactory platelet inhibition, 13% needed 60 mg/day, 8%
needed 70 mg/day, and 3% needed 100 mg/day. Platelet aggregation was found
to be inhibited in only 1.2% of the measurements in the patients receiving
placebo. Observation during treatment averaged 21 months; total
intention-to-treat follow-up averaged 25 months. For the combined outcome
events of transient ischemic attack, stroke, acute myocardial infarction,
and vascular death, aspirin reduced risk by 11% (95% confidence limits:
-38% to 48%, p greater than 0.1). Thus, there was no significant effect of
very-low- dose aspirin in our trial.
ARTICLES
Danish very-low-dose aspirin after carotid endarterectomy trial
Department of Neurology, Rigshospitalet, Copenhagen, Denmark.
This article has been cited by other articles:
 |
|
 |
|
  M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Thijs, R. Lemmens, and S. Fieuws Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review Stroke, May 1, 2008; 39(5): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vorchheimer and R. Becker Platelets in Atherothrombosis Mayo Clin. Proc., January 1, 2006; 81(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Touze, O. Varenne, G. Chatellier, S. Peyrard, P. M. Rothwell, and J.-L. Mas Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke: A Systematic Review and Meta-Analysis Stroke, December 1, 2005; 36(12): 2748 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tran and S. S. Anand Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease JAMA, October 20, 2004; 292(15): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Jackson and G. P. Clagett Antithrombotic Therapy in Peripheral Arterial Occlusive Disease Chest, January 1, 2001; 119 (2009): 283S - 299S. [Full Text] [PDF]
|
|
|
|
 |
|
 A. G Thrift, J. J McNeil, A. Forbes, and G. A Donnan Risk of primary intracerebral haemorrhage associated with aspirin and non-steroidal anti-inflammatory drugs: case-control study BMJ, March 20, 1999; 318(7186): 759 - 764. [Abstract] [Full Text]
|
|
|
|
|
|
J. He, P. K. Whelton, B. Vu, and M. J. Klag Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials JAMA, December 9, 1998; 280(22): 1930 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eccles, N. Freemantle, J. Mason, and t. N. o. E. A. G. D. Group North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care BMJ, April 25, 1998; 316(7140): 1303 - 1309. [Full Text]
|
|
|
|
 |
|
 J. Biller, W. M. Feinberg, J. E. Castaldo, A. D. Whittemore, R. E. Harbaugh, R. J. Dempsey, L. R. Caplan, T. F. Kresowik, D. B. Matchar, J. F. Toole, et al. Guidelines for Carotid Endarterectomy : A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association Circulation, February 10, 1998; 97(5): 501 - 509. [Full Text] [PDF]
|
|
|
|
|
|
J. Biller, W. M. Feinberg, J. E. Castaldo, A. D. Whittemore, R. E. Harbaugh, R. J. Dempsey, L. R. Caplan, T. F. Kresowik, D. B. Matchar, J. F. Toole, et al. Guidelines for Carotid Endarterectomy : A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association Stroke, February 1, 1998; 29(2): 554 - 562. [Full Text] [PDF]
|
|
|
|
 |
|
 H. J.M. Barnett, M. Eliasziw, and H. E. Meldrum Drugs and Surgery in the Prevention of Ischemic Stroke N. Engl. J. Med., January 26, 1995; 332(4): 238 - 248. [Full Text] [PDF]
|
|
|
|
|
|
Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. C Grotta Prevention and management of stroke Vascular Medicine, March 1, 1991; 2(1): 3 - 17. [PDF]
|
|
|
|
 |
|
 H. J. M. Barnett The Contribution of Multicenter Trials to Stroke Prevention and Treatment Arch Neurol, April 1, 1990; 47(4): 441 - 444. [Abstract] [PDF]
|
|
|
|
 |
|
 R. D. Cebul and J. P. Whisnant Carotid Endarterectomy Ann Intern Med, October 15, 1989; 111(8): 660 - 670. [Abstract] [PDF]
|
|